国产固定剂量复合剂治疗肺结核的临床近期效果观察

中国防痨杂志 ›› 2004, Vol. 26 ›› Issue (6): 341-343.

国产固定剂量复合剂治疗肺结核的临床近期效果观察

初乃惠；高孟秋；马丽萍；刘菲；吴晓光；王庆枫；聂理会；朱莉贞；

北京市结核病胸部肿瘤研究所北京 101149；

出版日期:2004-06-10 发布日期:2004-11-03

Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy

Chu Naihui,Gao Mengqiu,Ma Liping,et al.

Beijing Tubercu losis and Thoracic Tumor Institute,Beijing 101149

Online:2004-06-10 Published:2004-11-03

摘要/Abstract

摘要： 目的　评价国产固定剂量复合剂异烟肼利福平吡嗪酰胺/异烟肼利福平(2HRZ/4HR)的抗结核疗效及不良反应。方法将81例初治菌阳肺结核患者,随机分为治疗组(2HRZ/4HR)和对照组(2HRZ/4HR),观察近期痰菌阴转率、X线病灶改变及不良反应。结果治疗组和对照组2月痰菌阴转率分别达82.5%和65.7%;满疗程痰菌阴转率各为100.0%和88.6%;胸部X线明显改善,治疗组和对照组病灶吸收分别占92.7%和94.3%,两组空洞闭合率分别为63.2%和62.5%;治疗组和对照组各有2例和4例肝功异常。结论国产固定复合剂是一种安全、高效、易被患者接受、具有推广应用前景的抗结核药物。

关键词: 固定剂量复合剂, 结核,肺/药物疗法

Abstract: Objective To evaluate the treatment outcome and si de-effects of national fixed-dose compounds (2HRZ/4HR).Methods 81 new bacteriological positive pulmonary tuberculosis patients were divided r andomly into treatment group (42 cases) and control (39 cases) group.Results The sputum negative conversion rates at the 2nd month in the treatment and the control group were 82.5% and 65.7% respectively.And the rates at the end of the chemotherapy were 100.0% and 88.6% respectively.Chest ra diography showed remarkable improvement.The resolution of pulmonary lesions in t he treatment group and the control group accounted for 92.7% and 94.3% respectiv ely.The cavity closure rates were 63.2% in the treatment group and 62.5% in the control group.Two patients defaulted because of hepatic dysfunction in the t re atment group and 4 patients in the control’s.Conclusion Nation al fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy,saf ety and compliance in antituberculous chemotherapy,which could be recommended fo r wider use in tuberculosis control in China.

Key words: Fixed-dose compounds, Pulmonary tuberculosis/drug th erapy

初乃惠,高孟秋,马丽萍,刘菲,吴晓光,王庆枫,聂理会,朱莉贞,. 国产固定剂量复合剂治疗肺结核的临床近期效果观察[J]. 中国防痨杂志, 2004, 26(6): 341-343.

Chu Naihui,Gao Mengqiu,Ma Liping,et al.. Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy[J]. Chinese Journal of Antituberculosis, 2004, 26(6): 341-343.

[1]	马丽萍, 吴晓光, 初乃慧, 朱莉贞, 陕斌, 王敏, 王燕, 张文书, 李会军, 候栋7. 在DOTS管理下应用国产4药固定剂量复合剂治疗初治菌阳肺结核的可行性研究[J]. 中国防痨杂志, 2010, 32(5): 21-25.
[2]	钟球, 高翠南, 方兰君, 陈瑜晖, 李建伟, 莫卓鼎. 四联抗结核固定剂量复合剂的临床疗效研究[J]. 中国防痨杂志, 2010, 32(3): 162-167.
[3]	何铁牛, 韩永兴, 陈彬. 抗结核固定复合剂药物不良反应观察[J]. 中国防痨杂志, 2010, 32(12): 828-830.
[4]	成诗明,钟球,郑金凤,谢艳光,李晓凤,王伟,陈诚,徐敏,杜昕,. 固定剂量复合剂在国家结核病防治规划中的应用研究[J]. 中国防痨杂志, 2007, 29(2): 111-116.
[5]	谭卫国,杨应周,吴清芳,张玉华,管红云,钟球,王甦民,傅瑜,. 抗结核固定剂量复合剂与板式组合药治疗肺结核效果对比分析[J]. 中国防痨杂志, 2007, 29(2): 117-121.
[6]	钟球,黄桂清,张明,张日东,李建伟,. 固定剂量复合剂在省结核病防治规划中应用的研究[J]. 中国防痨杂志, 2006, 28(5): 274-277.
[7]	贺永鸿,成诗明,陈诚. 固定剂量复合剂治疗肺结核患者依从性调查与分析[J]. 中国防痨杂志, 2006, 28(3): 129-132.